Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1956 1
1961 1
1964 5
1966 1
1967 1
1968 1
1969 1
1970 2
1971 1
1972 6
1973 3
1974 8
1975 11
1976 10
1977 9
1978 18
1979 11
1980 14
1981 13
1982 16
1983 12
1984 33
1985 38
1986 29
1987 45
1988 58
1989 75
1990 80
1991 133
1992 140
1993 133
1994 159
1995 185
1996 188
1997 212
1998 271
1999 345
2000 394
2001 453
2002 585
2003 653
2004 747
2005 827
2006 1006
2007 1161
2008 1313
2009 1418
2010 1679
2011 1892
2012 1998
2013 2419
2014 2907
2015 3082
2016 3456
2017 3778
2018 4483
2019 5181
2020 6693
2021 7141
2022 6641
2023 6728
2024 3143

Text availability

Article attribute

Article type

Publication date

Search Results

64,451 results

Results by year

Filters applied: . Clear all
Page 1
Drug development for cystic fibrosis.
Sanders DB, Chmiel JF. Sanders DB, et al. Pediatr Pulmonol. 2021 Feb;56 Suppl 1:S10-S22. doi: 10.1002/ppul.25075. Pediatr Pulmonol. 2021. PMID: 32940969 Review.
Innovative approaches are required to continue to advance drug development in CF. This review provides a general overview of drug development from the preclinical phase through Phase IV. Special considerations with respect to CF are integrated into the …
Innovative approaches are required to continue to advance drug development in CF. This review provides a general overview of …
The myotonic dystrophy type 1 drug development pipeline: 2022 edition.
Pascual-Gilabert M, Artero R, López-Castel A. Pascual-Gilabert M, et al. Drug Discov Today. 2023 Mar;28(3):103489. doi: 10.1016/j.drudis.2023.103489. Epub 2023 Jan 9. Drug Discov Today. 2023. PMID: 36634841 Free article. Review.
The beginning of the 20th decade has witnessed an increase in drug development programs for myotonic dystrophy type 1 (DM1). We have collected nearly 20 candidate drugs with accomplished preclinical and clinical phases, updating our previous drug developme …
The beginning of the 20th decade has witnessed an increase in drug development programs for myotonic dystrophy type 1 (DM1). W …
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
Glassman PM, Balthasar JP. Glassman PM, et al. Drug Metab Pharmacokinet. 2019 Feb;34(1):3-13. doi: 10.1016/j.dmpk.2018.11.002. Epub 2018 Nov 22. Drug Metab Pharmacokinet. 2019. PMID: 30522890 Free PMC article. Review.
Finally, we conclude with a discussion of currently available PBPK models for mAbs that could be implemented in the drug development process....
Finally, we conclude with a discussion of currently available PBPK models for mAbs that could be implemented in the drug developme …
Allostery in Drug Development.
Cheng X, Jiang H. Cheng X, et al. Adv Exp Med Biol. 2019;1163:1-23. doi: 10.1007/978-981-13-8719-7_1. Adv Exp Med Biol. 2019. PMID: 31707697 Review.
We also review the state-of-the-art experimental and computational approaches used in allosteric drug development. The accumulated knowledge of allosteric regulation and the technical progress made in drug development will lead to an explosion of promi …
We also review the state-of-the-art experimental and computational approaches used in allosteric drug development. The accumul …
Drug development process and COVID-19 pandemic: Flourishing era of outsourcing.
Wasan H, Singh D, Reeta KH, Gupta P, Gupta YK. Wasan H, et al. Indian J Pharmacol. 2022 Sep-Oct;54(5):364-372. doi: 10.4103/ijp.ijp_318_22. Indian J Pharmacol. 2022. PMID: 36537406 Free PMC article. Review.
Traditional drug development is a tedious process with involvement of enormous cost and a high attrition rate. Outsourcing drug development services to contract research organizations (CROs) has become an important strategy for cost and risk reduction, …
Traditional drug development is a tedious process with involvement of enormous cost and a high attrition rate. Outsourcing …
Maternal-Fetal Drug Development: An Industry Perspective.
Burnham J, Darsey E. Burnham J, et al. J Clin Pharmacol. 2022 Sep;62 Suppl 1(Suppl 1):S18-S29. doi: 10.1002/jcph.2124. J Clin Pharmacol. 2022. PMID: 36106788 Free PMC article. Review.
However, clinical, regulatory, ethical, and drug development challenges are encountered when designing clinical trials that include pregnant women and their fetuses, in which innovative methods and trial designs are essential. This article provides an overview of an …
However, clinical, regulatory, ethical, and drug development challenges are encountered when designing clinical trials that in …
Schizophrenia: Antipsychotics and drug development.
Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Remington G, et al. Behav Brain Res. 2021 Sep 24;414:113507. doi: 10.1016/j.bbr.2021.113507. Epub 2021 Aug 3. Behav Brain Res. 2021. PMID: 34352293 Review.
Atypicality is reviewed in reference to its original definition, clozapine's role, and developments that now leave the concept's utility in question. In a similar fashion, drug development is reviewed in the context of the illness' multiple symptom domains, as well …
Atypicality is reviewed in reference to its original definition, clozapine's role, and developments that now leave the concept's utility in …
Model-Informed Drug Development in Pediatric Dose Selection.
Bi Y, Liu J, Li F, Yu J, Bhattaram A, Bewernitz M, Li RJ, Ahn J, Earp J, Ma L, Zhuang L, Yang Y, Zhang X, Zhu H, Wang Y. Bi Y, et al. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S60-S69. doi: 10.1002/jcph.1848. J Clin Pharmacol. 2021. PMID: 34185906 Review.
Model-informed drug development (MIDD) has been a powerful and efficient tool applied widely in pediatric drug development due to its ability to integrate and leverage existing knowledge from different sources to narrow knowledge gaps. The dose selecti …
Model-informed drug development (MIDD) has been a powerful and efficient tool applied widely in pediatric drug devel …
Drug Development for Asthma and COPD: A Regulatory Perspective.
Mann M, Meyer RJ. Mann M, et al. Respir Care. 2018 Jun;63(6):797-817. doi: 10.4187/respcare.06009. Respir Care. 2018. PMID: 29794212 Free article. Review.
This review addresses drug development intended to support United States clearance for asthma and COPD by explaining basic regulatory terms and broadly discussing the regulatory pathways to clearance. Some of the key clinical regulatory challenges that are faced by …
This review addresses drug development intended to support United States clearance for asthma and COPD by explaining basic reg …
64,451 results
You have reached the last available page of results. Please see the User Guide for more information.